News

Biocon and CIM have collaborated for almost a decade on an integrated program to manufacture and clinically evaluate recombinant proteins with the aim of building a portfolio based

ebrary claimed that it provides e-books and digital content services, from research and development to manufacturing and distribution, to marketing and sales, that can help pharmaceutical companies increase

Conscious-2 primary endpoint showed a non-significant relative risk reduction of 17% in favor of Clazosentan and the safety profile of Clazosentan in Conscious-2 was comparable to previous studies

Kikta is expected to augment ClinTec’s US operations and Global HQ management team to offer prospective pharmaceutical, biotech and medical device client’s guidance on their drug development and

The primary efficacy analysis will be conducted using the hybrid American College of Rheumatology, or ACR, score (hACR), which allows for a more comprehensive assessment of treatment benefit

The company has posted a net loss of $19.3m for the year ended 30 June 2010, or $0.83 loss per diluted share, compared to net loss of $22.37m,

SGN-35 is an antibody-drug conjugate (ADC) targeted to CD30. In the trial, 75% of the patients achieved an objective response as assessed by an independent central review, the

Prior to joining Aethlon, Frakes served as the chief financial officer for four public companies over a period of 16 years. Aethlon chief executive officer James Joyce said

The company said that if its AM152 IND got accepted by the FDA, it will be eligible to commence Phase 1 safety studies with the compound in healthy